Goldman Myla Lai - Jul 8, 2025 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Myla Lai-Goldman
Stock symbol
AKYA
Transactions as of
Jul 8, 2025
Transactions value $
$0
Form type
4
Date filed
7/10/2025, 08:37 PM
Previous filing
May 8, 2025
Next filing
Oct 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LAI GOLDMAN MYLA Director C/O AKOYA BIOSCIENCES, INC., 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH /s/ Myla Lai-Goldman 2025-07-10 0001168581

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Other -20K -100% 0 Jul 8, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy) Other $0 -39K -100% $0.00 0 Jul 8, 2025 Common Stock 39K $18.10 Direct F3, F4
transaction AKYA Stock Option (right to buy) Other $0 -30.5K -100% $0.00 0 Jul 8, 2025 Common Stock 30.5K $11.24 Direct F3, F4
transaction AKYA Stock Option (right to buy) Other $0 -56.3K -100% $0.00 0 Jul 8, 2025 Common Stock 56.3K $5.70 Direct F3, F4
transaction AKYA Stock Option (right to buy) Other $0 -50K -100% $0.00 0 Jul 8, 2025 Common Stock 50K $2.01 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Goldman Myla Lai is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2 In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3 Disposition of options pursuant to Merger Agreement.
F4 Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.